miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O

被引:51
作者
Chen, Binghai [1 ,2 ]
Duan, Lujing [3 ]
Yin, Guangming [1 ]
Tan, Jing [1 ]
Jiang, Xianzhen [1 ]
机构
[1] Cent S Univ, Xiang Ya Hosp 3, Dept Urol, Changsha 410000, Hunan, Peoples R China
[2] Jiangsu Univ, Affiliated Hosp, Dept Urol, Zhenjiang, Peoples R China
[3] Jiangsu Univ, Affiliated Hosp, Dept Endocrinol, Zhenjiang, Peoples R China
关键词
5-FU; Cdc2; Chemotherapy; MicroRNA; miR-381; Renal cell cancer; WEE1; GENE-EXPRESSION; DOWN-REGULATION; KINASE; CHECKPOINT; CARCINOMA; MICRORNA; RADIOSENSITIZATION; IDENTIFICATION; PHOSPHATASES; PD0166285;
D O I
10.1179/1973947813Y.0000000092
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Few researches on increase of chemotherapy sensitivity by microRNA (miRNA) were reported. We aim to investigate exact role of miR-381 in chemotherapy sensitivity of 5-fluorouracil (5-FU) in renal cancer cells. Methods: We investigated the cell survival, cell-cycle and apoptosis of 786-O and HK-2 cells treated with miR-381 and 5-FU. IC50 of 5-FU was calculated. To study apoptosis and G(2)/M arrest, we determined pHH3, mitotic index and caspase-3/7 activity. Results: We showed that miR-381 combined with 5-FU inhibited proliferation and potentiated the antitumour efficacies of 5-FU at tolerated concentration in vitro. miR-381 combined with 5-FU led to Cdc2 activation, mitotic catastrophe, and cell apoptosis through inhibitory WEE1. WEE1 was also validated as the direct target of miR-381. IC50 of 5-FU decreased significantly in the presence of miR-381. Conclusion: miR-381 increases sensitivity of 786-O cells to 5-FU by inhibitory WEE1 and increase of Cdc2 activity.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 1 条
  • [1] Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells-Cdc2 activity is up-regulated by targeting WEE1
    Chen, Binghai
    Duan, Lujing
    Yin, Guangming
    Tan, Jing
    Jiang, Xianzhen
    CLINICS, 2013, 68 (06) : 825 - 833